GW Pharmaceuticals to AIM - 28th June 2001
|
The London Stock Exchange is delighted to welcome GW Pharmaceuticals to AIM - the dynamic market designed to meet the needs of developing companies.
Dr. Geoffrey Guy and Dr Brian Whittle founded GW in 1998 - their aim is to develop a range of prescription medicines derived from cannabis. The company controls all aspects of product development including research, cultivation, extraction and formulation into drug form, clinical trials and regulatory issues.
Products of the company were first trialled in the UK in September 1999. By May 2001, GW entered into a pivotal phase III clinical trial programme for its Multiple Sclerosis product.
Dr Guy and Dr Whittle also founded Phytopharm plc - a plant based medicine company - in 1989. Phytopharm is listed on techMARK.
GW plan to use the proceeds from their listing to fund the expansion of late clinical trials, develop cultivation and production facilities, and accelerate research activities in both Europe and North America.
Placing Statistics
Placing price - 182p
Market cap at placing - 174.8m
For additional information, please contact:
Nomad/Nombro
Collins Stewart
Or visit:
<% newurl = "server.URLencode("www.gwpharm.com")" %>
www.gwpharm.com
|
|